EBC-46 Tumour Response by Histology: Which Cancer Types Show the Most Promise in Published Data
Published EBC-46 trial data spans multiple tumour types. Comparing response rates by histology reveals which cancer subtypes have shown the strongest signals in Phase I and II studies.
The Phase I/II clinical trial of tigilanol tiglate (EBC-46) in humans enrolled patients with a range of solid tumour histologies. While head and neck squamous cell carcinoma (HNSCC) was the most represented tumour type, the trial included patients with melanoma, breast cancer cutaneous metastases, and other accessible solid tumours. Examining response patterns by tumour type offers insight into where EBC-46 shows the strongest clinical signal — and where further investigation is most warranted.
Why Histology Matters for Intratumoral Agents
Intratumoral drugs like tigilanol tiglate work through direct tissue contact: the drug is injected into the tumour, and its effect depends on local drug distribution, tumour vascularisation, and the surrounding immune microenvironment. Unlike systemic drugs, where tumour biology determines drug delivery, intratumoral efficacy can vary significantly based on tumour texture (soft vs. fibrous), degree of vascularisation, and the composition of the tumour stroma.
Squamous cell carcinomas, for instance, tend to be well-vascularised and relatively accessible — properties that favour the rapid haemorrhagic necrosis that EBC-46 induces through PKC-delta activation. Fibrous, densely stroma-rich tumours may distribute the injectate less efficiently, potentially limiting the drug's contact with tumour vasculature.
Head and Neck SCC: The Leading Signal
The QBiotics Phase I/II study (published in Cancers, 2020) reported complete responses in several HNSCC patients at accessible tumour sites including the neck, parotid region, and oral cavity. The completeness of response — defined as 100% tumour volume reduction with no residual viable tissue — was one of the most compelling aspects of the data.
HNSCC tumours are frequently soft-tissue, accessible, and well-vascularised, which aligns with the pharmacodynamic profile of tigilanol tiglate. The characteristic 'eschar and slough' response — visible necrotic crust formation followed by wound healing — was consistently observed in this cohort and is considered an expected pharmacodynamic marker of drug activity.
Cutaneous Metastases: A Potentially Broad Indication
Several patients in the published trial had cutaneous or subcutaneous metastatic deposits from primary tumours including breast cancer. These lesions — accessible, measurable, and often multiple — represent a potentially broad indication for intratumoral agents. Response data from this subgroup, while limited by trial size, suggested that the drug's mechanism was not histology-specific: the vascular disruption effect operated across different tissue types when tumour architecture was accessible.
This has clinical significance. Cutaneous metastases are a significant quality-of-life problem across many cancer types — they can ulcerate, bleed, and cause localised pain. A well-tolerated intratumoral agent capable of inducing complete local responses would address an unmet need in palliative oncology, regardless of primary tumour histology.
Fibrous and Stroma-Dense Tumours: A Recognised Challenge
Not all tumour types respond equally to intratumoral agents. Desmoplastic tumours — characterised by dense fibrous stroma surrounding tumour nests — present a mechanical barrier to drug distribution. Pancreatic ductal adenocarcinoma is the canonical example, though it is not accessible for intratumoral injection in most cases. For accessible fibrous tumours (certain sarcomas, some thyroid metastases), the distribution challenge is a real limitation that protocol refinements — including injection volume optimisation — may partially address.
QBiotics' ongoing clinical programme, which focuses on HNSCC and may expand to other accessible tumour types, will generate the comparative histology data needed to formally characterise where EBC-46 performs best in human tissue.
Implications for the Supplement Category
It is important to note that this research involves pharmaceutical-grade intratumoral tigilanol tiglate — not oral dietary supplements. Blushwood berry extract supplements, such as those offered by Blushwood Health, are dietary products sold under DSHEA and are not intended to diagnose, treat, cure, or prevent any disease. The clinical research provides scientific context for understanding the compound; it does not validate the use of oral supplements for any medical condition.
Related Articles
→ Human Clinical Trials of EBC-46: What the Phase I/II Data Actually Shows
Citations
2. QBiotics Group — Clinical Development of Tigilanol Tiglate, QBiotics.com, accessed 2026.
3. NCI — Head and Neck Cancer Research Overview, National Cancer Institute, accessed 2026.
